Paul Quinlan Biography and Net Worth

Mr. Quinlan has served as our General Counsel, Chief Compliance Officer and Corporate Secretary since October 2020. He was also our General Counsel and Corporate Secretary from December 2017 to February 2020. Previously, Mr. Quinlan served as General Counsel and Secretary at TerraVia Holdings, Inc. (formerly Solazyme, Inc.) since 2010. From 2005 to 2010, Mr. Quinlan was General Counsel and Secretary at Metabolex, Inc. and from 2000 to 2005, Mr. Quinlan held various positions in the legal department at Maxygen, Inc., most recently that of Chief Corporate Securities Counsel. Prior to joining Maxygen, Mr. Quinlan was an associate at Cooley LLP and Cravath, Swaine & Moore LLP. Mr. Quinlan obtained a law degree from Columbia Law School and a M.Sc. in Medical Biophysics from the University of Toronto.

What is Paul T. Quinlan's net worth?: The estimated net worth of Paul T. Quinlan is at least $4.24 million as of September 16th, 2016. Mr. Quinlan owns 130,528 shares of CymaBay Therapeutics stock worth more than $4,239,549 as of April 27th. This net worth estimate does not reflect any other assets that Mr. Quinlan may own. Additionally, Mr. Quinlan receives an annual salary of $629,720.00 as General Counsel at CymaBay Therapeutics. Learn More about Paul T. Quinlan's net worth.
How old is Paul T. Quinlan?: Mr. Quinlan is currently 61 years old. There are 7 older executives and no younger executives at CymaBay Therapeutics. The oldest executive at CymaBay Therapeutics is Dr. Charles A. McWherter Ph.D., President of Research & Development and Chief Scientific Officer, who is 69 years old. Learn More on Paul T. Quinlan's age.
What is Paul T. Quinlan's salary?: As the General Counsel of CymaBay Therapeutics, Inc., Mr. Quinlan earns $629,720.00 per year. There are 2 executives that earn more than Mr. Quinlan. The highest earning executive at CymaBay Therapeutics is Mr. Sujal A. Shah, President, CEO & Director, who commands a salary of $1,040,000.00 per year. Learn More on Paul T. Quinlan's salary.
How do I contact Paul T. Quinlan?: The corporate mailing address for Mr. Quinlan and other CymaBay Therapeutics executives is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. CymaBay Therapeutics can also be reached via phone at (510) 293-8800 and via email at [email protected]. Learn More on Paul T. Quinlan's contact information.
Has Paul T. Quinlan been buying or selling shares of CymaBay Therapeutics?: Paul T. Quinlan has not been actively trading shares of CymaBay Therapeutics during the past quarter. Learn More on Paul T. Quinlan's trading history.
Who are CymaBay Therapeutics' active insiders?: CymaBay Therapeutics' insider roster includes Janet Dorling (Director), Dennis Kim (Insider), Charles McWherter (Insider), Daniel Menold (VP), Paul Quinlan (General Counsel), Sujal Shah (CEO), and Kurt von Emster (Director). Learn More on CymaBay Therapeutics' active insiders.
Are insiders buying or selling shares of CymaBay Therapeutics?: In the last year, insiders at the biopharmaceutical company sold shares 27 times. They sold a total of 480,648 shares worth more than $7,806,823.97. The most recent insider tranaction occured on February, 12th when Director Janet Dorling sold 6,000 shares worth more than $191,820.00. Insiders at CymaBay Therapeutics own 7.0% of the company. Learn More about insider trades at CymaBay Therapeutics.
Information on this page was last updated on 2/12/2024.

Paul T. Quinlan Insider Trading History at CymaBay Therapeutics

Paul T. Quinlan Buying and Selling Activity at CymaBay Therapeutics

CymaBay Therapeutics Company Overview

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

Today's Range

Now: $32.48

$32.48

50 Day Range

MA: $32.40

$32.17

$32.48

2 Week Range

Now: $32.48

$7.26

$32.50

Volume

73 shs

Average Volume

4,113,430 shs

Market Capitalization

$3.73 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.32

These AI trades triggered this morning (545% return)

From Prosper Trading Academy | Ad

If you think a market crash is possible in 2024, I don't know why you're not using this yet.

Click Here To Get Your Free Copy

Paul Quinlan Biography and Net Worth

What is Paul T. Quinlan's net worth?

How old is Paul T. Quinlan?

What is Paul T. Quinlan's salary?

How do I contact Paul T. Quinlan?

Has Paul T. Quinlan been buying or selling shares of CymaBay Therapeutics?

Who are CymaBay Therapeutics' active insiders?

Are insiders buying or selling shares of CymaBay Therapeutics?